

Belal Haschimi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8595868/publications.pdf>

Version: 2024-02-01

11
papers

229
citations

933447

10
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

204
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection of the recently emerged synthetic cannabinoid 4F-MDMB-BINACA in "legal high" products and human urine specimens. <i>Drug Testing and Analysis</i> , 2019, 11, 1377-1386.	2.6	44
2	A transnational perspective on the evolution of the synthetic cannabinoid receptor agonists market: Comparing prison and general populations. <i>Drug Testing and Analysis</i> , 2021, 13, 841-852.	2.6	28
3	Detection and phase I metabolism of the 7-azaindole-derived synthetic cannabinoid 5F-AB-7AICA including a preliminary pharmacokinetic evaluation. <i>Drug Testing and Analysis</i> , 2020, 12, 78-91.	2.6	21
4	Four cases of death involving the novel synthetic cannabinoid 5F-Cumyl-PEGACLONE. <i>Forensic Toxicology</i> , 2020, 38, 314-326.	2.4	21
5	Impact of legislation on NPS markets in Germany " The rise and fall of 5F-ADB. <i>Drug Testing and Analysis</i> , 2020, 12, 853-856.	2.6	21
6	Cumyl-CBMICA: A new synthetic cannabinoid receptor agonist containing a cyclobutyl methyl side chain. <i>Drug Testing and Analysis</i> , 2021, 13, 208-216.	2.6	21
7	Development and validation of a rapid LC-MS/MS method for the detection of 182 novel psychoactive substances in whole blood. <i>Drug Testing and Analysis</i> , 2022, 14, 202-223.	2.6	19
8	The Novel Psychoactive Substance Cumyl-CH-MEGACLONE: Human Phase-I Metabolism, Basic Pharmacological Characterization and Comparison to Other Synthetic Cannabinoid Receptor Agonists with a ¹³ -Carboline-1-One Core. <i>Journal of Analytical Toxicology</i> , 2021, 45, 277-290.	2.8	15
9	New synthetic cannabinoids carrying a cyclobutyl methyl side chain: Human Phase I metabolism and data on human cannabinoid receptor 1 binding and activation of Cumyl-CBMICA and Cumyl-CBMINACA. <i>Drug Testing and Analysis</i> , 2021, 13, 1499-1515.	2.6	15
10	Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4-PICA, MDMB-4-PINACA, ADB-4-PINACA, and MMB-4-CN-BUTINACA using a combination of binding and different CB1 receptor activation assays. Part III: The G protein pathway and critical comparison of different assays. <i>Drug Testing and Analysis</i> , 2021, 13, 1412-1429.	2.6	14
11	Extraordinary long detection window of a synthetic cannabinoid metabolite in human urine " Potential impact on therapeutic decisions. <i>Drug Testing and Analysis</i> , 2020, 12, 391-396.	2.6	10